Our Co-Founder and Chief Scientific Officer, Philipp Spycher, Ph.D., will be speaking about the development of novel dual-payload antibody-drug conjugates (ADCs) at the 2nd annual ADC Linker & Conjugation Summit on Thursday, August 22nd at 12pm ET. For more information and to register, visit here: https://lnkd.in/eQWiftp7
Araris Biotech AG
Biotechnologieforschung
Au, ZH 5.142 Follower:innen
Building tomorrow's antibody-drug conjugates (ADCs)
Info
Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.
- Website
-
https://www.ararisbiotech.com
Externer Link zu Araris Biotech AG
- Branche
- Biotechnologieforschung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Au, ZH
- Art
- Privatunternehmen
- Gegründet
- 2019
- Spezialgebiete
- Antibody Drug Conjugates und ADCs
Orte
-
Primär
Riedhofstrasse 11
Au, ZH 8804, CH
Beschäftigte von Araris Biotech AG
Updates
-
Don’t forget to sign up for an insightful webinar where experts, including our own Co-founder & CSO, Philipp Spycher, Ph.D., will discuss immunotherapy advancements that are transforming cancer treatment. The panelists will explore the current landscape of immunotherapy research, including insights into recent developments and obstacles encountered within the field. To register for free and learn more, please visit here: https://lnkd.in/ggyq7k6S
-
We’re thrilled to be included as one of the top seven innovative companies revolutionizing antibody-drug conjugate (ADC) drug development in this report from Clarivate for Life Sciences & Healthcare. For more information, download the full report here: https://lnkd.in/eCSaAWtu
Araris Biotech AG, with its proprietary conjugation technology and linker-payload platforms to efficiently develop and advance next-generation ADCs, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. Araris' drug attachment is simple, site-specific and has the potential to stably accommodate various drug-load combinations without altering the pharmacokinetic profile of the antibody, resulting in ADCs with a high therapeutic window. Why is Araris Biotech a company to watch? Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/eCSaAWtu #oncology #cancertreatement #biotech #pharma #companiestowatch
-
Our Co-Founder and Chief Scientific Officer, Philipp Spycher, Ph.D., will be a panelist on Drug Target Review's “Immunotherapy Advancements: Transforming Cancer Treatment” webinar on July 29th at 10am EDT. Join the webinar to hear more about Araris’ antibody-drug conjugates as a revolutionary approach in cancer treatment. To register for free and learn more, please visit here: https://lnkd.in/ggyq7k6S
-
In case you missed it, we presented data at the @American Association for Cancer Research (AACR) Annual Meeting 2024 on two novel dual TOP1i ADCs targeting HER2 and NaPi2b that showed high stability and high anti-tumor activity in mouse models. Read more here: https://bit.ly/3Kp6tBq
-
We’re pleased to announce we’ve appointed Ulf Grawunder, Ph.D. to our scientific advisory board. His wealth of knowledge and experience in the #ADC space will be instrumental as we continue to innovate our proprietary ADC technology and develop our pipeline of next-generation ADC therapies. Read more: https://bit.ly/3xgdUaT
-
Our chief business officer, Filippo Mulinacci, and our acting-CEO and co-founder, Dragan Grabulovski, will be at BIO International Convention June 3-6, 2024 at the San Diego Convention Center. Contact us at [email protected] or send us an invite via the One-on-One BIO Partnering system to discuss our development of novel ADCs
-
In case you missed it, we’ll be in San Diego June 3-6, 2024 at the BIO International conference. Reach out to us to schedule a 1:1 meeting and learn more about our approach to ADC development: For more information, email us at [email protected]
-
Here at Araris, we are developing next-generation ADCs with improved efficacy and tolerability to create therapeutic options with potentially superior inhibition of tumor growth for patients. Learn more about our solution here: https://lnkd.in/eXFAHgxM
-
We are pioneering a proprietary ADC conjugation technology and linker-payload platform that will give us the ability to develop highly stable and precisely defined ADCs in only one step. Learn more here: https://lnkd.in/eXFAHgxM